VEPPANU™ (vepdegestrant), FDA-Approved for Treatment of ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
– Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by Rigel Pharmaceuticals as the hub and a limited distribution specialty pharmacy provider for VEPPANU™ (vepdegestrant).
INLURIYO™ (imlunestrant) FDA-Approved for Treatment of ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for Inluriyo, an oral estrogen receptor antagonist for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer.
TRUQAP (capivasertib), FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson
Biologics by McKesson was selected as a specialty pharmacy provider for TRUQAP, approved with fulvestrant for certain biomarker-altered HR-positive, HER2-negative advanced or metastatic breast cancer.